European Archives of Psychiatry and Clinical Neuroscience最新文献

{"title":"Persistent increased severity of cannabis use disorder symptoms in adolescents compared to adults: a one-year longitudinal study.","authors":"Rachel Lees, Will Lawn, Kat Petrilli, Amelia Brown, Katie Trinci, Anya Borissova, Shelan Ofori, Claire Mokrysz, H Valerie Curran, Lindsey A Hines, Tom P Freeman","doi":"10.1007/s00406-024-01806-y","DOIUrl":"10.1007/s00406-024-01806-y","url":null,"abstract":"<p><p>Adolescence is a developmental period characterised by increased vulnerability to cannabis use disorder (CUD). However, previous investigations of this vulnerability have relied on cross-sectional comparisons and lack a detailed assessment of cannabis quantity, a potentially important confounding factor. Here, we aimed to investigate the one-year course of CUD in adolescents compared to adults who currently use cannabis, adjusting for a comprehensive measure of cannabis quantity. Data are from a one-year observational longitudinal study (CannTeen) of adolescents and adults who currently used cannabis regularly with five waves of assessment at 3-monthly intervals, based in London, UK. Participants were n = 70 adults (26-29, 45.7% female), who did not regularly use cannabis when they were under age 18, and n = 76 adolescents (16-17, 50.0% female). The exposure was adolescent (compared to adult) frequent cannabis use. The primary outcome was CUD symptoms measured using the cannabis use disorder identification test revised (CUDIT-R) at five time points. Models were adjusted for cannabis quantity using mean weekly standard THC units (one unit = 5 mg THC). Other covariates included gender, and whether each session occurred before or during the COVID-19 pandemic. In models adjusted for pre-registered covariates, adolescents scored 3.7 points higher on the CUDIT-R compared to the adult group across the 5 assessment waves (3.66 95% CIs 1.99, 5.34). There was also evidence of a linear reduction in symptoms over time in both groups (-0.47, 95%CIs -0.67, -0.27). Adolescents had persistently increased CUD symptoms compared to adults across the 12-month period. This association was robust after adjusting for the quantity of cannabis consumed and other covariates.</p>","PeriodicalId":11822,"journal":{"name":"European Archives of Psychiatry and Clinical Neuroscience","volume":" ","pages":"397-406"},"PeriodicalIF":3.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11910442/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140862593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychiatric antecedents in young patients with first episode psychosis: what relevance for clinical outcomes?","authors":"Lorenzo Pelizza, Fabio Catalano, Emanuela Leuci, Emanuela Quattrone, Derna Palmisano, Simona Pupo, Giuseppina Paulillo, Clara Pellegrini, Pietro Pellegrini, Marco Menchetti","doi":"10.1007/s00406-025-01981-6","DOIUrl":"https://doi.org/10.1007/s00406-025-01981-6","url":null,"abstract":"<p><p>Examining psychiatric antecedents and help-seeking behavior for people with First Episode Psychosis (FEP) could help understand determinants for timely care pathways, decrease the \"Duration of Untreated Psychosis\" (DUP), and consequently improve their prognosis. The aims of this study were: (1) to calculate the proportion of FEP participants with previous contact with mental healthcare services recruited within a specialized \"Early Intervention in Psychosis\" service, and (2) to longitudinally compare sociodemographic, clinical, and treatment parameters between FEP patients with and without psychiatric antecedents across a 2-year follow-up period. All participants (aged 12-35 years) were enrolled within the \"Parma Early Psychosis\" (Pr-EP) program. At baseline, they completed the Health of the Nation Outcome Scale (HoNOS). A mixed-design ANOVA and a Kaplan-Meier survival analysis were used. Of the 489 FEP participants, 204 (41.7%) patients had prior contact with mental health services. In 83% of cases, a care discontinuity was observed. Main psychiatric antecedents at entry were personality disorders (32.8%), anxious-depressive disorder (28.9%), conduct disorder (16.2%), and learning disorder (9.8%). FEP subjects with antecedents were more likely to receive a diagnosis of schizophrenia at baseline. Having previous contact with psychiatric services resulted to be a predictor of poorer clinical and functional outcome. It is very important to carefully monitor mental health suffering and related help-seeking-behavior in young patients typically manifested in their early 20s, especially in terms of psychosis prevention. Particular attention should also be given to service engagement as care continuity within adolescent-adult transition.</p>","PeriodicalId":11822,"journal":{"name":"European Archives of Psychiatry and Clinical Neuroscience","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143531321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trajectories of lipid profile with cognitive function: 12-year follow-up of Guangzhou Biobank cohort study.","authors":"Yu Meng Tian, Wei Sen Zhang, Chao Qiang Jiang, Feng Zhu, Ya Li Jin, Shiu Lun Au Yeung, Jiao Wang, Kar Keung Cheng, Tai Hing Lam, Lin Xu","doi":"10.1007/s00406-025-01974-5","DOIUrl":"https://doi.org/10.1007/s00406-025-01974-5","url":null,"abstract":"<p><p>Studies on the trajectories of lipid profile with cognitive decline are scarce and inconsistent. We examined this association and explored potential effect modification. Lipid profiles including high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG) and total cholesterol (TC) were measured at baseline, first and second follow-ups, and classified into trajectory groups. Immediate, delayed memory recall and cognitive function were assessed by the immediate (IWRT) and delayed 10-word recall test (DWRT), and mini-mental state examination (MMSE), respectively, at baseline and follow-ups, and converted into standardized scores. Linear mixed-effect model was used. Results show that elevated HDL-C was associated with increasing annual change rates in DWRT and MMSE scores (β (95% confidence intervals) = 0.005 (-0.001 to 0.011) SD/year and 0.020 (0.014 to 0.027) SD/year, respectively), while LDL-C and TC were associated with a decrease in DWRT scores (-0.005 (-0.008 to -0.001) SD/year and - 0.009 (-0.011 to -0.006) SD/year, respectively). Moderate-increasing HDL-C, high-decreasing LDL-C or moderate-decreasing TC trajectories were associated with increases in DWRT, IWRT and MMSE scores. Stronger associations were identified for HDL-C with an increase in MMSE scores within the lower family income group and for LDL-C with a decrease in IWRT scores among individuals taking lipid-lowering drug. In conclusion, HDL-C was associated with improvements, while LDL-C and TC with decline in memory and cognitive function. Increasing HDL-C and decreasing LDL-C and TC trajectories predicted better memory and cognitive performance. The observed effect modifications highlight the importance of personalized approaches in lipid management to optimize cognitive outcomes.</p>","PeriodicalId":11822,"journal":{"name":"European Archives of Psychiatry and Clinical Neuroscience","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Objectifying persistent subjective cognitive impairment following COVID-19 infection: cross-sectional data from an outpatient memory-clinic in Germany.","authors":"Luca Tarantini, Corina Möller, Victoria Schiestl, Sabrina Sordon, Michael Noll-Hussong, Miriam Wittemann, Nicole Menzie, Matthias Riemenschneider","doi":"10.1007/s00406-025-01978-1","DOIUrl":"https://doi.org/10.1007/s00406-025-01978-1","url":null,"abstract":"<p><strong>Objective: </strong>Subjective cognitive impairment is frequently reported by patients experiencing Post-COVID symptoms. This study aims to assess objective impairment in attention, memory, and executive functions among these patients. Further, we investigated potential determinants of objective cognitive impairment.</p><p><strong>Methods: </strong>In this cross-sectional study, standardized neuropsychological testing (Vienna Testing System), assessment of cognitive symptom aggravation, psychiatric anamnesis, and psychometrics (BDI-II, Fatigue Severity Scale) were conducted in 229 patients who voluntarily presented to our outpatient memory-clinic due to subjective cognitive impairment following COVID-19. Blood-samples were collected to assess peripheral immune markers (IL-6, CRP) and APOE-ε4 genotype.</p><p><strong>Results: </strong>Objective cognitive impairment in at least one domain was present in 39% of the patients and 47% showed symptoms of moderate or severe depression. The APOE-ε4 allele was present in 32% of the patients. Higher rates of depressive symptoms (OR = 1.41, 95%-CI = 1.02-1.95) and higher burden of the APOE-ε4 allele (OR = 3.29, 95%-CI = 1.51-7.40) predicted objective cognitive impairment, regardless of age, sex, years of formal education, time since infection, and medication for diabetes or hypertension. Fatigue severity, acute COVID-19 severity or inflammation markers had no impact.</p><p><strong>Conclusions: </strong>In our study, subjective cognitive impairment following COVID-19 was more likely associated with high rates of depression rather than relatively low rates of objective cognitive performance. Thus, the study emphasizes the necessity for extensive neuropsychological testing and evaluation of depression when examining Post-COVID patients in clinical practice. Further, the link between objective cognitive impairment, depression and APOE-ε4 does not appear to be specific to Post-COVID symptoms. Therefore, depression- and APOE-ε4-mediated neurodegenerative pathomechanisms might be a promising therapeutical target.</p>","PeriodicalId":11822,"journal":{"name":"European Archives of Psychiatry and Clinical Neuroscience","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143531320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The associations of brain-derived neurotrophic factor (BDNF) levels with psychopathology and lipid metabolism parameters in adolescents with major depressive disorder.","authors":"Lewei Liu, Mingru Hao, Haiyun Yu, Yinghan Tian, Cheng Yang, Haojie Fan, Xin Zhao, Feng Geng, Daming Mo, Lei Xia, Huanzhong Liu","doi":"10.1007/s00406-025-01984-3","DOIUrl":"https://doi.org/10.1007/s00406-025-01984-3","url":null,"abstract":"<p><p>Brain-derived neurotrophic factor (BDNF) is crucial for the growth, differentiation and maintenance of neuronal systems, which is closely associated with major depressive disorder (MDD). The objective of this study was to investigate the BDNF levels and their associations with psychopathology and lipid metabolism parameters in adolescents with MDD. From January to December 2021, the study included 141 adolescents with MDD and 90 healthy controls (HCs). The Center for Epidemiological Studies Depression Scale (CES-D), the Insomnia Severity Index Scale (ISI), the Epworth Sleepiness Scale (ESS) and the Positive and Negative Suicidal Ideation Scale (PANSI) were used to assess depressive symptoms, insomnia, excessive daytime sleepiness, and suicidal ideation, respectively. BDNF levels and lipid metabolism parameters were also measured. Compared to HCs, adolescents with MDD had significantly lower BDNF levels (p < 0.001). In patients, BDNF levels were positively correlated with age, BMI, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C); and negatively correlated with the scores of CES-D and ISI (all p < 0.05). The results of the multivariate linear regression analyses indicated that BDNF levels were positively associated with age (β = 0.198, t = 2.447, p = 0.016), first-episode MDD (β = 0.176, t = 2.234, p = 0.027) and TC level (β = 0.240, t = 3.048, p = 0.003), and negatively associated with the scores of ESS (β = -0.171, t = -2.203, p = 0.029) and ISI (β = -0.231, t = -2.996, p = 0.003). Of note, the associations between BDNF and psychopathology were observed only in female and first-episode patients. BDNF levels were decreased in adolescents with MDD. Patients with low BDNF levels were in a more severe psychiatric state and had changes in lipid metabolism parameters. This study provided preliminary evidence that BDNF may play a role in the onset and progression of MDD.</p>","PeriodicalId":11822,"journal":{"name":"European Archives of Psychiatry and Clinical Neuroscience","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gender differences in clinical correlates of glucose disturbance in patients with first-episode and drug-naïve major depressive disorder.","authors":"Shiwang Chen, Jianan Zhou, XiaoE Lang, Xiang-Yang Zhang","doi":"10.1007/s00406-025-01980-7","DOIUrl":"https://doi.org/10.1007/s00406-025-01980-7","url":null,"abstract":"<p><p>Gender differences in glucose metabolism disorders in patients with major depressive disorder (MDD) have been rarely studied. In this study we investigated gender differences in the prevalence of glucose metabolism disorders and associated factors in first-episode and drug naïve (FEDN) MDD patients in a Chinese Han population. In this cross-sectional study, a total of 1718 FEDN MDD outpatients were recruited, and demographic and clinical data were collected. All subjects were scored using the Hamilton Depression Rating Scale (HAMD), Hamilton Anxiety Rating Scale (HAMA) and the Positive and Negative Syndrome Scale (PANSS) positive subscale to assess clinical symptoms. Female MDD patients were older, present with symptoms at an older age, were more likely to be married and had more psychotic symptoms than male MDD patients. There was no significant difference in the prevalence of glucose metabolism disorders between female patients (14.16%) and male patients (12.59%) (p > 0.05). In both male and female groups, patients with glucose metabolism disorders had higher HAMD score, HAMA score, suicide attempts, and psychotic symptoms than patients without glucose metabolism disorders (all p < 0.05). However, only in female group, patients with glucose metabolism disorders had more severe anxiety symptoms than patients without glucose metabolism disorders. Furthermore, binary logistic regression analysis showed that psychotic symptoms and suicide attempts were independently associated with glucose metabolism disorders in male MDD patients, while suicide attempts and HAMD score was independently associated with glucose metabolism disorders in female MDD patients. Our findings showed no gender differences in the prevalence of glucose metabolism disorders in patients with FEDN MDD. However, there were gender difference in the clinical correlates of glucose metabolism disorders in FEDN MDD patients.</p>","PeriodicalId":11822,"journal":{"name":"European Archives of Psychiatry and Clinical Neuroscience","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying suicidal ideation in Chinese higher vocational students using machine learning: a cross-sectional survey.","authors":"Kun Jin, Tao Zeng, Menghui Gao, Chuwei Chen, Songyan Zhang, Furu Liu, Jinghui Bao, Jindong Chen, Renrong Wu, Jingping Zhao, Jing Huang","doi":"10.1007/s00406-025-01973-6","DOIUrl":"https://doi.org/10.1007/s00406-025-01973-6","url":null,"abstract":"<p><p>Suicide has emerged as a major societal issue. Studies indicate that Chinese higher vocational students experience higher levels of suicidal ideation (SI) compared with the general population. This study aims to explore the feasibility of using machine learning (ML) to identify SI and to determine the most suitable model. This cross-sectional study was conducted at an engineering university, predominantly attended by male students. First, we compared demographic and clinical characteristics between participants with and without SI. We then applied 10 ML models to identify the presence of SI. The study included 1,408 (89.51%) male and 165 (10.49%) female students. The prevalence of SI was 20.34% (320/1573). Individuals with SI were more likely to be female, spend more time playing computer games, have poor academic scores, have poor relationships with teachers and schoolmates, experience more severe mental distress, have more serious childhood trauma, and have histories of non-suicidal self-injury (NSSI)-related acts or thoughts (all P < .001). Most ML models showed excellent performance, particularly the random forest model, which achieved an ROC AUC of 0.97, a specificity of 96.00%, and a sensitivity of 90.63%. Consistent attention should be given to Chinese higher vocational students with NSSI ideas, bipolar disorder symptoms, and depression symptoms. ML can be used effectively in clinical practice to recognise higher vocational students who exhibit SI.</p>","PeriodicalId":11822,"journal":{"name":"European Archives of Psychiatry and Clinical Neuroscience","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of rTMS compared to SSRI as early treatment of depression - study protocol of a randomized controlled trial (Early-TMS).","authors":"Julia Becker-Sadzio, Bettina Brendel, Simone Weller, Edmund Bornheimer, Ulrike Mehlig, Frank Padberg, Ulrike Vogelmann, Thomas Kammer, Wolfgang Strube, Peter Martus, Andreas J Fallgatter, Christian Plewnia","doi":"10.1007/s00406-025-01975-4","DOIUrl":"https://doi.org/10.1007/s00406-025-01975-4","url":null,"abstract":"<p><p>Psychotherapy and antidepressant medication are considered first-line treatment options for major depressive disorder (MDD). However, a high proportion of patients do not respond to initial treatment, underlining the need for alternative treatment methods. Repetitive transcranial magnetic stimulation (rTMS) has been established in the treatment of MDD, but the available evidence is limited to forms of MDD with varying degrees of treatment resistance. Randomized-controlled trials (RCT) investigating first-line treatment with rTMS in comparison with first-line antidepressant medication are warranted to further position rTMS within current treatment algorithms for MDD. In this two-stage, therapy response-adapted, randomized multi-center phase 2 rater blinded trial, 106 medication-naïve patients suffering from MDD will be enrolled. In Stage I, participants receive one of the two treatment options for four weeks: either daily bilateral theta burst stimulation (TBS), a patterned and time-saving form of rTMS, or antidepressant medication with selective serotonin reuptake inhibitors (SSRI). The allocation to Stage II occurs therapy response-adapted. Therefore, patients either receive maintenance treatment or will be switched to the respective other treatment arm. Primary outcome is the comparison between the two study arms with regard to therapy response measured by the Montgomery-Asberg Depression Rating Scale (MADRS) after 4 weeks at the end of Stage I. The aim of the study is to provide reliable first evidence and effect size measures of rTMS as first-line treatment compared to SSRI treatment. Positive results will help to implement rTMS in early stages of MDD. Trial registration: ClinicalTrials.gov ID: NCT06545474, August 15, 2024.</p>","PeriodicalId":11822,"journal":{"name":"European Archives of Psychiatry and Clinical Neuroscience","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Silexan is well-tolerated for long-term use in adults and for treatment of adolescents: a real-world data analysis.","authors":"Hans-Peter Volz, Thomas Rosemann, Martin Burkart, Thorsten Reineke, Karel Kostev","doi":"10.1007/s00406-025-01967-4","DOIUrl":"https://doi.org/10.1007/s00406-025-01967-4","url":null,"abstract":"<p><p>For Silexan, a proprietary preparation of Lavandula angustifolia flowers, efficacy and tolerability in adults with anxiety disorders was demonstrated in clinical trials lasting up to 10 weeks. The present study investigated the extent and tolerability of long-term and adolescent use in real world. For the retrospective analysis of patients with a first prescription for Silexan, case-based information provided by office-based physicians from Germany was extracted from the IQVIA Disease Analyzer (DA) database. Patients treated by general practitioners and specialists were analysed. Proportions of patients with long-term therapy (> 3 months, > 6 months) and adolescent patients (aged 12-17 years) were determined, incidence rates of diagnoses or complaints compatible with known adverse effects before and after therapy initiation were estimated. Long-term usage was additionally analysed by data from the Swiss longitudinal prescription (LRx) database, which covers approximately 50% of pharmacies and most physicians of Switzerland. 67,340 adults (DA 36,664, LRx 30,676) with at least one Silexan prescription were analysed. Of these, 4.0% (DA) and 27.6% (LRx) had more than 3 months of therapy. DA data included 483 (1.3%) adolescent patients. Diagnoses or complaints compatible with known adverse effects were rare among long-term or adolescent Silexan users and did not differ significantly during the period of Silexan therapy compared to an equivalent period before Silexan therapy. Our findings suggest that Silexan is a frequently used and well-tolerated treatment option for individuals requiring extended relief from their symptoms. It might provide a well-tolerated pharmacologic treatment option for adolescents.</p>","PeriodicalId":11822,"journal":{"name":"European Archives of Psychiatry and Clinical Neuroscience","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to electroconvulsive therapy is associated with a more diverse oral microbiome- a prospective longitudinal cohort pilot study.","authors":"Christoph Ammer-Herrmenau, Jacob Hamm, Albrecht Neesse, Kilian Günther, Matthias Besse, David Zilles-Wegner","doi":"10.1007/s00406-025-01976-3","DOIUrl":"https://doi.org/10.1007/s00406-025-01976-3","url":null,"abstract":"<p><p>Recently it has been shown that psychiatric disorders are associated with changes in the host microbiome. Little is known about the association of electroconvulsive therapy (ECT) and microbiome alterations. In our pilot-study, 15 patients with severe or treatment resistant depression were prospectively recruited and oral swabs were collected pre- and post-ECT. Compared to a control group, ECT did not lead to a significant microbial shift in longitudinal samples (p = 0.65). However, alpha diversity measurements significantly differed between responders and non-responders before ECT (observed species p = 0.014, Shannon p = 0.03) and after ECT (observed species p = 0.015, Shannon p = 0.13).</p>","PeriodicalId":11822,"journal":{"name":"European Archives of Psychiatry and Clinical Neuroscience","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}